AQR Capital Management - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
AQR Capital Management ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$2,832,744
-3.5%
41,615
+14.9%
0.01%0.0%
Q2 2023$2,934,065
-51.7%
36,223
-56.2%
0.01%
-53.8%
Q1 2023$6,073,086
-55.5%
82,627
-49.9%
0.01%
-58.1%
Q4 2022$13,643,867
+31.8%
164,781
+352.0%
0.03%
+24.0%
Q3 2022$10,354,000
-25.2%
36,456
-10.0%
0.02%
-19.4%
Q2 2022$13,843,000
-25.4%
40,522
-5.4%
0.03%
-11.4%
Q1 2022$18,552,000
-39.7%
42,842
-29.1%
0.04%
-37.5%
Q4 2021$30,764,000
+39.5%
60,465
+32.8%
0.06%
+36.6%
Q3 2021$22,060,000
+43.3%
45,524
+32.0%
0.04%
+51.9%
Q2 2021$15,398,000
-10.0%
34,482
-23.0%
0.03%
-3.6%
Q1 2021$17,112,000
-4.4%
44,804
-20.5%
0.03%
-12.5%
Q4 2020$17,891,000
+27.8%
56,352
-0.3%
0.03%
+33.3%
Q3 2020$13,997,000
-15.2%
56,503
-12.4%
0.02%
-11.1%
Q2 2020$16,497,000
-10.9%
64,520
-33.9%
0.03%
-12.9%
Q1 2020$18,517,000
+9.7%
97,651
+25.8%
0.03%
+63.2%
Q4 2019$16,872,000
-30.4%
77,608
-37.3%
0.02%
-34.5%
Q3 2019$24,234,000
-40.2%
123,851
-36.9%
0.03%
-35.6%
Q2 2019$40,552,000
+1.0%
196,142
-3.1%
0.04%
+4.7%
Q1 2019$40,133,000
-25.6%
202,487
-45.7%
0.04%
-31.7%
Q4 2018$53,955,000
+16.8%
372,820
+64.7%
0.06%
+43.2%
Q3 2018$46,212,000
+175.3%
226,409
+99.5%
0.04%
+158.8%
Q2 2018$16,787,000
+103.5%
113,463
+107.8%
0.02%
+88.9%
Q1 2018$8,249,000
+624.2%
54,615
+518.1%
0.01%
+800.0%
Q4 2017$1,139,000
+48.7%
8,836
+39.4%
0.00%0.0%
Q3 2017$766,000
-13.7%
6,337
-16.1%
0.00%0.0%
Q2 2017$888,000
+13.3%
7,556
-2.0%
0.00%0.0%
Q1 2017$784,000
+52.2%
7,708
+63.9%
0.00%0.0%
Q3 2016$515,000
-16.9%
4,702
-25.4%
0.00%0.0%
Q2 2015$620,000
-1.9%
6,3000.0%0.00%0.0%
Q1 2015$632,000
-56.6%
6,300
-60.0%
0.00%
-66.7%
Q4 2014$1,455,00015,7430.00%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders